Ritanserin suppresses acute myeloid leukemia by inhibiting DGK α to downregulate phospholipase D and the Jak-Stat/MAPK pathway
AbstractRefractory or relapsed (R/R) AML is the most challenging form of AML to treat. Due to frequent genetic mutations, therapy alternatives are limited. Here, we identified the role of ritanserin and its target DGK α in AML. Several AML cell lines and primary patient cells were treated with ritanserin and subjected to cell proliferation, apoptosis and gene analyses with CCK-8 assay, Annexin V/PI assay and Western blotting, respectively. We also evaluated the function of the ritanserin target diacylglycerol ki nase alpha (DGKα) in AML by bioinformatics. In vitro experiments have revealed that ritanserin inhibits AML pr...
Source: Hormones and Cancer - July 1, 2023 Category: Cancer & Oncology Source Type: research
TRAF inhibition drives cancer cell apoptosis and improves retinoic acid sensitivity in multiple cancers models
This study aimed to investigate the relationship between TRAFs and retinoic acid sensitivity in various cancers. Here, we revealed that TRAFs’ expression varied significantly across The Cancer Genome Atlas (TCGA) cancer cohorts and human cancer cell lines. Add itionally, inhibiting TRAF4, TRAF5, or TRAF6 improved retinoic acid sensitivity and reduced colony formation in ovarian cancer and melanoma cells. Mechanistically, knocking down TRAF4, TRAF5, or TRAF6 in retinoic acid-treated cancer cell lines increased the levels of procaspase 9 and induced cell ap optosis. Further in vivo studies using the SK-OV-3 and MeWo xenogr...
Source: Hormones and Cancer - June 30, 2023 Category: Cancer & Oncology Source Type: research
Acute myeloid leukemia cells and MSC-derived exosomes inhibiting transformation in myelodysplastic syndrome
ConclusionUltrafiltration is a proper methodology in extracting exosomes. The exosomes of AML origin and MSC origin may play a role in MDS leukemia transformation via targeting TNF- α/ROS-Caspase3 pathway. (Source: Hormones and Cancer)
Source: Hormones and Cancer - June 29, 2023 Category: Cancer & Oncology Source Type: research
A modified melanoma-molGPA scoring model: assessment of survival after and efficacy of different radiotherapy modalities in patients with melanoma brain metastases
ConclusionWe propose a modified model that accurately distinguishes the prognosis of patients with MBMs and guides decision-making for radiotherapy. Based on this novel model, WBRT should be cautiously selected for high-risk patients. (Source: Hormones and Cancer)
Source: Hormones and Cancer - June 29, 2023 Category: Cancer & Oncology Source Type: research
The biological significance of cuproptosis-key gene MTF1 in pan-cancer and its inhibitory effects on ROS-mediated cell death of liver hepatocellular carcinoma
In this study, we conducted the comprehensive analysis to evaluate the profiles of MTF1 in pan-cancer. For example, TIMER2.0, TNMplot and GEPIA2.0 were employed to analyze the expression values of MTF1 in pan-cancer. The methylation levels of MTF1 were evaluated via UALCAN and DiseaseMeth version 2.0 databases. The mutation profiles of MTF1 in pan-cancers were analyzed using cBioPortal. GEPIA2.0, Kaplan –Meier plotter and cBioPortal were also used to explore the roles of MTF1 in cancer prognosis. We found that high MTF1 expression was related to poor prognosis of liver hepatocellular carcinoma (LIHC) and brain lower grad...
Source: Hormones and Cancer - June 28, 2023 Category: Cancer & Oncology Source Type: research
Serum extracellular vesicles derived hsa-miR-320d as an indicator for progression of clear cell renal cell carcinoma
ConclusionsSerum EVs derived hsa-miR-320d as a liquid biomarker exhibits significant potential for identifying the recurrence or metastasis of ccRCC, as well as hsa-miR-320d promotes ccRCC cells migration and invasion. (Source: Hormones and Cancer)
Source: Hormones and Cancer - June 28, 2023 Category: Cancer & Oncology Source Type: research
Human epidermal growth factor 2 overexpressed alpha-fetoprotein-producing-gastric cancer
ConclusionHER2 overexpressed AFP-GC consisted of a mixed type of histology, which showed a better prognosis. The results presented that HER2 status in AFP-GC is one of the molecular candidates to improve the prognosis. (Source: Hormones and Cancer)
Source: Hormones and Cancer - June 24, 2023 Category: Cancer & Oncology Source Type: research
MTHFR act as a potential cancer biomarker in immune checkpoints blockades, heterogeneity, tumor microenvironment and immune infiltration
ConclusionsMTHFR could predict the response of immune checkpoints blockades, heterogeneity, tumor microenvironment and immune infiltration. (Source: Hormones and Cancer)
Source: Hormones and Cancer - June 24, 2023 Category: Cancer & Oncology Source Type: research
Development and validation of a predictive model in diagnosis and prognosis of primary glioblastoma patients based on Homeobox A family
ConclusionHOXA family has diagnostic values, and the HOXAs-based nomogram model is effective in survival prediction, providing a novel approach to support the treatment of GBM patients. (Source: Hormones and Cancer)
Source: Hormones and Cancer - June 23, 2023 Category: Cancer & Oncology Source Type: research
TOM40 regulates the progression of nasopharyngeal carcinoma through ROS-mediated AKT/mTOR and p53 signaling
AbstractNasopharyngeal carcinoma (NPC) is a prevalent cancer in Southern China, North Africa, and Southeast Asia. The translocase of the outer membrane (TOM) 40 is a transporter of mitochondrial proteins, and is involved in ovarian cancer cell growth. However, its role in the progression of NPC is still unclear. We found that TOM40 levels were upregulated in NPC tissues and multiple NPC cell lines. In addition, high TOM40 expression in the tumor tissues was associated with poor overall survival and disease specific survival. TOM40 knockdown in the NPC cell lines inhibited their proliferation in vitro and in vivo. Furthermo...
Source: Hormones and Cancer - June 23, 2023 Category: Cancer & Oncology Source Type: research
Progress and prospects in research and clinical practice of hormone receptor-positive, HER-2-negative breast cancer with BRCA1/2 mutations
AbstractBreast cancer (BC) is a heterogeneous disease that is the most common cancer in women worldwide. However, precise subtyping and corresponding treatments have improved patient outcomes. Hormone receptor (HR)-positive, human epidermal growth factor receptor type 2 (HER2)-negative (HR+/HER2-) BC with BRCA1 and/or BRCA2 mutations (BRCA1/2m) is a unique BC subset with dual drivers: homologous recombination deficiency and hormone receptor signaling. Wild-type BRCA1/2 suppresses estrogen receptor-mediated signaling. Loss-of-function mutations inBRCA1/2 release estrogen receptor suppression, leading to reduced sensitivity ...
Source: Hormones and Cancer - June 23, 2023 Category: Cancer & Oncology Source Type: research
HSF1 is a novel prognostic biomarker in high-risk prostate cancer that correlates with ferroptosis
ConclusionCollectively, our findings suggest that HSF1 exerts a significant influence on PC. HSF1 may represent a promising biomarker for identifying high-risk PC, and the elimination of HSF1 could potentially enhance the therapeutic effectiveness of RSL3. (Source: Hormones and Cancer)
Source: Hormones and Cancer - June 23, 2023 Category: Cancer & Oncology Source Type: research
Survival nomogram for patients with thymic squamous cell carcinoma, based on the SEER database and an external validation cohort
ConclusionWe developed a nomogram to predict 3- and 5 year survival rate for TSCC. This nomogram provides a convenient and reliable tool for assessing the condition of patients with TSCC and assisting clinicians in making decisions. (Source: Hormones and Cancer)
Source: Hormones and Cancer - June 20, 2023 Category: Cancer & Oncology Source Type: research
Efficacy and safety of different PD-1 inhibitors in combination with lenvatinib in the treatment of unresectable primary liver cancer: a multicentre retrospective study
This study included a total of 176 patients who received a combination of lenvatinib and PD-1 inhibitors. Of these, 103 patients received camrelizumab, 44 received tislelizumab, 20 received sintilimab, and 9 received pembrolizumab. There was no significant difference in the pairwise comparison of camrel izumab, tislelizumab, sintilimab, and pembrolizumab using Kaplan–Meier survival analysis. Adverse events occurred in 40 (22.7%) patients (grade ≥ 3, 2.3%). The incidence of grade 3 adverse events among the four PD-1 inhibitor groups was below 5%. Camrelizumab, tislelizumab, sintilimab, and p embrolizumab are viable ...
Source: Hormones and Cancer - June 19, 2023 Category: Cancer & Oncology Source Type: research
Molecular mechanisms of syncytin-1 in tumors and placental development related diseases
AbstractHuman endogenous retroviruses (HERVs) have evolved from exogenous retroviruses and account for approximately 8% of the human genome. A growing number of findings suggest that the abnormal expression of HERV genes is associated with schizophrenia, multiple sclerosis, endometriosis, breast cancer, bladder cancer and other diseases. HERV-W env (syncytin-1) is a membrane glycoprotein which plays an important role in placental development. It includes embryo implantation, fusion of syncytiotrophoblasts and of fertilized eggs, and immune response. The abnormal expression of syncytin-1 is related to placental development-...
Source: Hormones and Cancer - June 16, 2023 Category: Cancer & Oncology Source Type: research
